Benjamin Yerxa
Director/Board Member at CLEARSIDE BIOMEDICAL, INC.
Net worth: 22 626 $ as of 2024-04-29
Profile
Benjamin R.
Yerxa is the founder of Envisia Therapeutics, Inc. (founded in 2013) and Opus Genetics, Inc. (founded in 2021).
He held the title of President at Envisia Therapeutics, Inc. from 2013 to 2017.
Currently, Dr. Yerxa is the Chief Executive Officer at Retinal Degeneration Fund since 2018.
He is also the Chairman of RainBio, Inc., Director of The North Carolina Biotechnology Center, Independent Director of Clearside Biomedical, Inc., Director of Nacuity Pharmaceuticals, Inc., Director of SparingVision SAS, and Director of Vedere Bio II, Inc. Dr. Yerxa previously served as the Chief Executive Officer of The Foundation Fighting Blindness, Inc. from 2017 to 2022.
He was also the EVP, Chief Research & Development Officer at Inspire Pharmaceuticals, Inc. from 2009 to 2010.
Dr. Yerxa has a doctorate degree from the University of California, Irvine and an undergraduate degree from the University of California San Diego.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-05-14 | 17,957 ( 0.02% ) | 22 626 $ | 2024-04-29 |
Benjamin Yerxa active positions
Companies | Position | Start |
---|---|---|
CLEARSIDE BIOMEDICAL, INC. | Director/Board Member | 2022-03-02 |
The North Carolina Biotechnology Center
The North Carolina Biotechnology Center Internet Software/ServicesTechnology Services The North Carolina Biotechnology Center provides research and education grants. Its services include financing, technology assessment, business planning, and marketing strategies implementation. The company was founded in 1984 and is headquartered in Research Triangle Park, NC. | Director/Board Member | 2010-10-31 |
SparingVision SAS
SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | Director/Board Member | - |
Vedere Bio II, Inc.
Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation. | Director/Board Member | - |
RainBio, Inc.
RainBio, Inc. BiotechnologyHealth Technology Part of CalciMedica, Inc., RainBio, Inc. is a gene therapy company based in Raleigh, NC. RainBio, Inc. focuses on developing novel, sight-saving treatments for blinding corneal diseases. RainBio's lead program, RBIO-1, targets corneal blindness in mucopolysaccharidosis I (MPS I), a rare genetic disorder in children. Gary Jay Sternberg has been the CEO of the company since October 12, 2021. RainBio was acquired by Graybug Vision, Inc. on May 10, 2022. | Chairman | - |
Opus Genetics, Inc.
Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Chief Executive Officer | - |
Retinal Degeneration Fund | Chief Executive Officer | 2018-09-30 |
Nacuity Pharmaceuticals, Inc.
Nacuity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nacuity Pharmaceuticals, Inc. develops and markets pharmaceutical products. The company is headquartered in Fort Worth, TX. | Director/Board Member | - |
Former positions of Benjamin Yerxa
Companies | Position | End |
---|---|---|
The Foundation Fighting Blindness, Inc.
The Foundation Fighting Blindness, Inc. Miscellaneous Commercial ServicesCommercial Services The Foundation Fighting Blindness, Inc. provides preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration and usher syndrome. The firm also provides provide information on retinal degenerative diseases to all who request it, in order to increase knowledge and awareness of these diseases. It has locations in Columbia, Denver, Libertyville, New York, Plano, Raleigh and Santa Monica. The company was founded on September 16, 1971 and is headquartered in Columbia, MD. | Chief Executive Officer | 2022-06-30 |
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - |
░░░░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - |
Training of Benjamin Yerxa
University of California, Irvine | Doctorate Degree |
University of California San Diego | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
CLEARSIDE BIOMEDICAL, INC. | Health Technology |
Private companies | 12 |
---|---|
Inspire Pharmaceuticals, Inc.
Inspire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Inspire Pharmaceuticals, Inc. operated as a biopharmaceutical company. It discovered and developed pharmaceutical products to treat diseases that results from deficiencies in the body's natural mechanisms of mucosal hydration. The company was founded by Kendall Harden, Richard C. Boucher, Andre L. Lamotte, H. Jefferson Leighton and Terrance G. McGuire and was headquartered in Whitehouse Station, NJ. | Health Technology |
Liquidia Technologies, Inc.
Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Health Technology |
The North Carolina Biotechnology Center
The North Carolina Biotechnology Center Internet Software/ServicesTechnology Services The North Carolina Biotechnology Center provides research and education grants. Its services include financing, technology assessment, business planning, and marketing strategies implementation. The company was founded in 1984 and is headquartered in Research Triangle Park, NC. | Technology Services |
The Foundation Fighting Blindness, Inc.
The Foundation Fighting Blindness, Inc. Miscellaneous Commercial ServicesCommercial Services The Foundation Fighting Blindness, Inc. provides preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration and usher syndrome. The firm also provides provide information on retinal degenerative diseases to all who request it, in order to increase knowledge and awareness of these diseases. It has locations in Columbia, Denver, Libertyville, New York, Plano, Raleigh and Santa Monica. The company was founded on September 16, 1971 and is headquartered in Columbia, MD. | Commercial Services |
Burroughs Wellcome | |
Envisia Therapeutics, Inc.
Envisia Therapeutics, Inc. BiotechnologyHealth Technology Envisia Therapeutics, Inc. develops novel ocular therapies. It provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic and chemical. The company was founded by 2013 is headquartered in Morrisville, NC. | Health Technology |
Nacuity Pharmaceuticals, Inc.
Nacuity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nacuity Pharmaceuticals, Inc. develops and markets pharmaceutical products. The company is headquartered in Fort Worth, TX. | Health Technology |
SparingVision SAS
SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | Health Technology |
Retinal Degeneration Fund | |
RainBio, Inc.
RainBio, Inc. BiotechnologyHealth Technology Part of CalciMedica, Inc., RainBio, Inc. is a gene therapy company based in Raleigh, NC. RainBio, Inc. focuses on developing novel, sight-saving treatments for blinding corneal diseases. RainBio's lead program, RBIO-1, targets corneal blindness in mucopolysaccharidosis I (MPS I), a rare genetic disorder in children. Gary Jay Sternberg has been the CEO of the company since October 12, 2021. RainBio was acquired by Graybug Vision, Inc. on May 10, 2022. | Health Technology |
Vedere Bio II, Inc.
Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation. | Commercial Services |
Opus Genetics, Inc.
Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Health Technology |
- Stock Market
- Insiders
- Benjamin Yerxa